-
2024-512369-14-00
4
Non-small cell lung cancer (NSCLC).
-
2023-510163-35-00
5
Acute Alcoholic hepatitis
-
2025-523555-66-00
5
Myelofibrosis
-
2025-524181-26-00
4
relapsed/refractory multiple myeloma
-
2025-524646-94-00
11
Obstetrics – Preeclampsia
-
2025-523269-31-00
3
2026-06-02
Hormone receptor-positive early breast cancer in post-menopausal women
-
2024-512436-29-00
11
2026-03-27
CARDIOVASCULAR DISEASES
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2024-519706-13-00
6
2026-01-26
Patients with Stable or Unstable coronary syndromes who have undergone
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2025-521040-37-00
5
2025-11-26
HER2-positive early breast cancer
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
-
2025-523804-62-00
5
2026-04-28
Obesity
-
2025-521117-88-00
5
2026-03-11
Cardiovascular Disease
-
2025-522421-36-00
6
2026-02-27
Acute coronary syndrome
-
2025-520897-21-00
10
2026-02-25
Multiple Myeloma
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-520276-10-00
5
2025-09-04
Non-constipated Irritable Bowel Syndrome (IBS)